Clinical Trials Browser

Recurrence × Breast × 30 days × Clear all

NCT07478705 2026-03-17

EINSTEIN-TNBC

Phase NA Not yet recruiting

Recurrence, Triple Negative Breast Neoplasms

NCT03742245 2026-03-16

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT06704659 2026-03-09

RAY-no-BAN

Phase NA Recruiting

Breast Neoplasms, Recurrence

NCT07458204 2026-03-09

EPPIL

Phase 2 Not yet recruiting

Recurrence, Triple Negative Breast Neoplasms

NCT06760637 2026-03-02

FourLight-3

Phase 3 Recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT02926690 2026-02-25

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

Phase 1 Recruiting

Breast Neoplasms, Recurrence, Triple Negative Breast Neoplasms

NCT05537740 2026-02-23

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Recurrence, Triple Negative Breast Neoplasms